18.17
+7.45%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tandem Diabetes Care
From its filings with the US Securities and Exchange Commission
Tandem Diabetes Care is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TNDM. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $1.01bn and a net loss of $204.7m. At that date it held total assets of $881.1m and shareholders' equity of $155.2m. By business, Supplies and other brought in 54.3% of revenue, followed by Pump at 45.7%. By region, United States accounted for 69.7%, followed by International at 30.3%.
Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management. We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide. Our strategy is to offer flexibility and choice in intelligent insulin delivery systems through an accessible portfolio of market-leading pumps, applications and insights. In support of this strategy, our Tandem pump platforms include t:slim X2 and Tandem Mobi (Mobi), both of which feature Control-IQ+ advanced hybrid closed-loop technology.
Diabetes can be challenging to manage. Unlike most therapies, insulin requirements can vary greatly and can be affected by many factors, such as type or quantity of food eaten, illness, stress and exercise. Preventing and managing fluctuations in blood glucose levels between hypoglycemia, or low blood glucose levels, and hyperglycemia, or high blood glucose levels, is often time consuming and stressful.
There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. Insulin pumps are intended to more closely resemble the physiologic function of a healthy pancreas and use rapid-acting insulin to fulfill both mealtime (bolus) and background (basal) requirements. Insulin pump systems are typically considered either durable or disposable.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 13 Nov 2013
- Employees
- 2,500
- Website
- tandemdiabetes.com ↗
- Head office
- 12400 HIGH BLUFF DRIVE, San Diego, CA, 92130
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Rebecca RobertsonIndependent Chairman of the Board$343,448
- Mr. John SheridanPresident, Chief Executive Officer, Director, since 2013$8.5m
- Ms. Leigh VossellerChief Financial Officer, Executive Vice President, Treasurer, since 2018$2.5m
- Mr. Jean-Claude KyrillosChief Operating Officer, Executive Vice President$2.4m
- Ms. Susan MorrisonExecutive Vice President, Chief Administrative Officer$2.0m
- Ms. Shannon HansenExecutive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary
- Ms. Elizabeth GasserExecutive Vice President and Chief Strategy and Product Officer$2.0m
- Mr. Mark NovaraExecutive Vice President and Chief Commercial Officer$802,745
- Mr. Rick CarpenterChief Technical Officer
- Mr. Myoung ChaIndependent Director$288,448
- Ms. Peyton HowellIndependent Director$298,948
- Mr. Joao MalagueiraIndependent Director$289,948
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 28
- Social
- 56
- Governance
- 72
- Women in the workforce
- 58.2%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tandem Diabetes Care Inc is known for its continuous technological innovation in the field of diabetes care. This enables the company to develop advanced and user-friendly products that cater to the needs of patients.
- The company has established a strong market presence in the diabetes care industry. It has successfully penetrated the market and gained a significant share, thanks to its high-quality products and comprehensive support services.
- Tandem Diabetes Care Inc has formed strategic collaborations with key stakeholders, including healthcare professionals, advocacy groups, and technology companies. These partnerships enhance the company's competitive advantage and facilitate product development.
Weaknesses
- The company operates in a highly regulated industry, which poses challenges in terms of complying with various regulatory requirements. Delays or non-compliance with regulations can impact product launch timelines and revenue generation.
- Tandem Diabetes Care Inc primarily focuses on insulin pumps and associated products, which limits its product portfolio compared to some competitors. Diversification into other areas of diabetes care may be necessary to address evolving customer needs.
Opportunities
- The increasing prevalence of diabetes globally presents an opportunity for Tandem Diabetes Care Inc to expand its market reach. By offering innovative and affordable solutions, the company can capture a larger share of the growing customer base.
- Advancements in technology, such as artificial intelligence and data analytics, can be leveraged by Tandem Diabetes Care Inc. These advancements can lead to the development of smarter, more personalized diabetes management solutions.
Threats
- The diabetes care market is highly competitive, with numerous established players and new entrants. Tandem Diabetes Care Inc faces the risk of losing market share to competitors who offer similar products and services.
- The healthcare industry is experiencing increasing pricing pressures, and this can impact Tandem Diabetes Care Inc's profitability. The company needs to effectively manage costs and optimize its pricing strategy to remain competitive.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.